MarketEubacterium eligens
Company Profile

Eubacterium eligens

Eubacterium eligens is a motile, obligate anaerobic, Gram-positive, rod-shaped mesophilic bacteria that lives in the human gut microbiome. In 1974, W.E.C Moore and Lillian V. Holdeman isolated and identified over 100 bacterial species from human feces, including E. eligens. The genus Eubacterium inhabits normal gut microbiota and contributes to anti-inflammatory secretions. E. eligens is unlike most Firmicutes species in that it can degrade pectin, which is usually more common among Bacteroidetes.

Characteristics
Taxonomy & phylogeny Eubacterium eligens is a member of the Bacillota (previously Firmicutes) phylum, which is one of two phyla which constitute more than 90% of microflora in the human gut. Characteristics of this phylum include low GC content in the DNA and Gram-positivity. Within the class Clostridia, E. eligens is placed in the order Clostridiales, which includes a large variety of anaerobic bacteria with varying metabolic capabilities. E. eligens is a member of the Eubacterium genus, a phylogenetically and phenotypically diverse genus. The genus was first proposed in 1938 by French bacteriologist Prévot, grouping together beneficial bacteria from human feces. This finding prompted the potential renaming of E. eligens to Lachnospira eligens. Holdeman and Moore worked in the Anaerobe Lab at Virginia Tech where they were able to isolate and define almost 200 new microbes from the human intestinal tract. E. eligens was isolated and described alongside 12 other unknown anaerobic species after being discovered during studies of the human fecal flora. Characterization was based on growth on or reaction to 32 different substrates by the isolated bacterium. BacDive establishes that E. eligens performs arginine and urea hydrolysis, nitrate reduction, and utilizes tryptophan as an energy source. What is known about the metabolism of E. eligens generally centers around its ability to break down carbohydrates, which makes it heterotrophic. Studies have shown that bacteria in the gut microbiota – which is where E. eligens can be found – interact with carbohydrates. In terms of testing the carbon acquisition of E. eligens specifically, other studies have shown this species outcompete other species in piglet fecal samples when piglets were fed sugar beet pulp as well as fructooligosaccharide, which were the only sources of carbon available to the gut microbiota. Additional research has also supported that this bacteria metabolizes the pectin in sugar beets and apples, which is a polysaccharide often found in fruit. Because of its metabolism, many of the genes found and studied in E. eligens focus on fermentation of carbohydrates. It has several genes that encode for enzymes that are intended to break down various carbohydrates, especially pectin. Genomics Eubacterium eligens has a total of 2,723 genes which constitute 2,613 protein genes, 66 RNA genes, and 44 pseudogenes. It consists of 2.83 Mb and can undergo 959 enzymatic reactions. The Eubacterium species E. rectale, E. hallii, E. ventriosum, E. eligens, E. coprostanoligenes, and E. limosum are the most closely related to one another with DNA G+C content of the genus varying from 30 to 57 percent. Kageyama and Benno found success in using nested PCR, a universal primer pair, and subsequent amplification of the bacterial sample using species-specific primers. The scientists used an assembler known as Athena, which builds high-quality genome drafts from a single shotgun sequencing operation by using barcode information from read clouds. == Applications ==
Applications
Eubacterium eligens emerges as a key component of gut microbiota health with potential implications for battling major health challenges such as obesity, metabolic syndrome, diabetes, and cardiovascular diseases. This species demonstrates a strongly negative correlation with abdominal visceral fat area (VFA) and is associated with a decrease in Type 1 Diabetes (T1D) risk. Furthermore, it has been linked to lower triglyceride levels and positively correlates with HDL-C levels, emphasizing its potential role in mitigating metabolic syndrome and cardiovascular risk inherent with obesity. The notable connections between reduced VFA, decreased T1D risk, and improved lipid profiles underscores its potential as a critical ally in managing these conditions. Moreover, the ability of E. eligens to produce anti-inflammatory compounds opens promising therapeutic avenues for treating inflammatory disorders, supporting its potential as a beneficial probiotic. Research has also revealed that Eubacterium species, including E. eligens and E. rectale, positively impact health markers such as reduced frailty and improved cognitive ability, alongside an increase in the production of short branched chain fatty acid. Understanding E. eligens paves the way to novel probiotic and therapeutic interventions, highlighting its significance beyond the scientific community to potentially transform public health approaches to diet, obesity management, and immune regulation, offering new horizons in preventative and curative health measures. == Ecological role in human health ==
Ecological role in human health
Not much is known about the role of E. eligens, but experiments have shown that it is prolific in the colon. It has been reported that several human health conditions are associated with gut dysbiosis, which can modify the abundance of Eubacterium in the gut microbiome. Studies have indicated a significant correlation between the prevalence of E. eligens in the gut microbiome and specific dietary fibers. These findings highlight the relationship between E. eligens and dietary practices. Eubacterium is one of the many possible gut microbial taxa that degrade dietary fiber, though E. eligens is one of the only Firmicutes to degrade pectin. They have also been found to have a negative association with stomach fat, meaning the more E. eligens one has in their microbiome, the less visceral fat they tend to have. == References ==
tickerdossier.comtickerdossier.substack.com